Bulletin
Investor Alert

New York Markets Close in:

Market Snapshot Winners and Losers

Deciphera Pharmaceuticals Inc.

NAS: DCPH

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
Deciphera Pharmaceuticals Inc.

Market open

 --Real time quotes

Jul 7, 2022, 12:46 p.m.

DCPH
/zigman2/quotes/203556943/composite

$

13.83

Change

-0.10 -0.68%

Volume

Volume 233,191

Real time quotes

/zigman2/quotes/203556943/composite

Previous close

$ 13.92

$ 13.83

Change

-0.10 -0.68%

Day low

Day high

$13.64

$14.12

Open

52 week low

52 week high

$6.51

$37.99

Open
Income Statement Balance Sheet Cash Flow Statement

Annual Financials for Deciphera Pharmaceuticals Inc.

View Ratios
Fiscal year is January-December. All values USD millions. 20172018201920202021 5-year trend
Sales/Revenue --25M42.09M96.15M
Cost of Goods Sold (COGS) incl. D&A 150,000317,000-5.36M9.39M
COGS excluding D&A ---225,0002.93M
Depreciation & Amortization Expense 150,000317,000830,0005.14M6.46M
Depreciation 150,000317,000830,0005.14M6.46M
Amortization of Intangibles -----
Gross Income (150,000)(317,000)-36.72M86.76M
20172018201920202021 5-year trend
SG&A Expense 50.79M103.78M224.9M307.91M360.63M
Research & Development 39.51M82.89M156.78M196.67M231.83M
Other SG&A 11.27M20.9M68.12M111.25M-
Other Operating Expense -----
Unusual Expense ----26.2M
EBIT after Unusual Expense ----(300.08M)
Non Operating Income/Expense 746,0004.33M8.54M4.7M113,000
Non-Operating Interest Income -----
Equity in Affiliates (Pretax) -----
Interest Expense 95,00084,00067,000--
Gross Interest Expense 95,00084,00067,000--
Interest Capitalized -----
Pretax Income (50.28M)(99.85M)(192.26M)(266.49M)(299.96M)
Income Tax -----
Income Tax - Current Domestic -----
Income Tax - Current Foreign -----
Income Tax - Deferred Domestic -----
Income Tax - Deferred Foreign -----
Income Tax Credits -----
Equity in Affiliates -----
Other After Tax Income (Expense) -----
Consolidated Net Income (50.28M)(99.85M)(192.26M)(266.49M)(299.96M)
Minority Interest Expense -----
Net Income (50.28M)(99.85M)(192.26M)(266.49M)(299.96M)
Extraordinaries & Discontinued Operations -----
Extra Items & Gain/Loss Sale Of Assets -----
Cumulative Effect - Accounting Chg -----
Discontinued Operations -----
Net Income After Extraordinaries (50.28M)(99.85M)(192.26M)(266.49M)(299.96M)
Preferred Dividends -----
Net Income Available to Common (50.28M)(99.85M)(192.26M)(266.49M)(299.96M)
EPS (Basic) (2.99)(2.82)(4.48)(4.78)(5.16)
Basic Shares Outstanding 16.79M35.39M42.87M55.78M58.08M
EPS (Diluted) (2.99)(2.82)(4.48)(4.78)(5.16)
Diluted Shares Outstanding 16.79M35.39M42.87M55.78M58.08M
EBITDA (50.79M)(103.78M)(199.9M)(266.05M)(267.42M)
Copyright 2022 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Link to MarketWatch's Slice.